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Carcinoid tumours are rare with an annual incidence of 1.3 per 100,000 in the N. Ireland
population.' Carcinoid tumours are unusual in that hepatic metastases arecompatible with
a 20 to 40% five year survival.2 Nevertheless, most patients become symptomatic when
hepatic metastasis occurs. The resulting local symptoms and those of the carcinoid
syndrome (where hepatic metastasis can be found in more than 95% of cases) greatly
reduce thequality ofthepatient's life.341It is therefore usual to treat such cases aggressively
with somatostatin analogues and other anti-serotonin agents, chemotherapy, surgical
debulkingandhepatic arteryocclusion (by ligation, temporaryocclusionorembolisation).
The latteriseffective ashepatic neoplasms arealmostsolely suppliedbythehepatic artery.6
The resultant selective tumour necrosis produces effective palliation ofsymptoms, which
may be prolonged due to the slow growing nature of the carcinoid tumour.7
The following case report presents an unusual post-embolisation complication (hepatic
abscess formation). The overall management of carcinoid hepatic metastases is briefly
discussed.
CASE REPORT
A 61 year old man presented in 1987 with haemoptysis. A right lower lobe bronchial
carcinoid tumour was discovered and subsequently resected. Overthe next few months he
developed diarrhoea, nocturnal wheeze and flushing. In 1989, investigation disclosed
deranged liverfunction tests (LFTs), raised urinary 5-hydroxyindole acetic acid (5-HIAA)
and raised plasma pancreatic polypeptide (PPP). An alcohol provocation test induced
marked flushing which was greatly reduced by injection ofa somatostatin analogue. There
was no evidence of secretion of 5-hydroxytryptamine, prostaglandins, insulin, gastrin,
vasoactive intestinal peptide, ACTH, parathormone or other active peptides, which may
occur with carcinoid tumours of foregut embryonic origin. Four hepatic metastases were
revealed on abdominal ultrasound (three in the right lobe and one in the left lobe). Intra-
heptic arterial chemotherapy combined with somatostatin was used at this time with good
symptomatic control.
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Fig /. Chest X-ray showing hepatic abscess as gas-fluid level under right hernidiaphragmn.
Fig 2. CT scan showing hepatic abscess with gas in liver substance.
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Fig 3. Post-operative CT scan after resection and drainage showing fluid-filled cavity in right hepatic lobe.
In early 1992 there was symptomatic deterioration combined with biochemical and
radiological evidence of tumour recurrence. In October 1992 he was admitted to hospital
with pain in the right upper quadrant (RUQ) ofthe abdomen and evidence ofa right basal
pneumonia. Following treatment of the pneumonia, hepatic artery embolisation using
particulate polyvinylchloride (PVC) was carried out on a large right lobar metastasis. He
subsequently developed a short lived episode of vomiting and abdominal pain which
settled withsymptomatic treatment. Anabdominal ultrasound scanpriortodischargeatten
days post-embolisation revealed an eight centimetre embolised lesion with noevidence of
complications.
Fifteen days later he was re-admitted with malaise, RUQ pain and tenderness, and
constipation. ChestX-ray(Figure 1)revealedanair-fluidlevelundertherighthemidiaphragm
and abdominal films showed hepatic mottling with gas shadows. These findings were
consistent with thedevelopment ofan aseptic abscess in the liverwith gas formation. This
was confirmed on computerised tomography (CT) which revealed that the embolised
lesion was now liquid in attenuation values with areas ofgas giving rise to a "soapbubble"
appearance (Figure 2).
Based on worsening clinical and radiological findings, rupture ofthe abscess was thought
to be imminent with the risk ofcarcinoid crisis orperitonitis. A formal drainageprocedure
was therefore carried out with resection of the necrotic right lobar metastasis under
somatostatin and antibiotic cover. Post-operative recovery in the intensive care unit was
uneventful.
© The Ulster Medical Society, 1995.
187The Ulster Medical Journal
Apost-operativeCTscandemonstratedmultiplesmallhepaticmetastasesandasignificantly
improved fluid filled cavity in the right lobe ofthe liver (Figure 3). He was discharged on
maintenance somatostatin andhas remained well since, with flushing ashisonlycomplaint.
DISCUSSION
In Northern Ireland there is a central diagnostic laboratory and register collecting data on
neuroendocrine tumours. There were 368 such tumours in the province between 1970 and
1985, of which 318 were carcinoids and 28 (9%) arose in the lung.' Carcinoid tumours are
slow growing neuroendocrine tumours." They occasionally produce local symptoms (e.g.
haemoptysis with a pulmonary carcinoid, obstruction with an appendiceal carcinoid) but
usually produce symptoms secondary to hormone secretion.9 Eighty percent ofcarcinoid
tumours are "midgut" in origin and secreted hormones are thus subject to hepatic first pass
metabolism."' Such tumours are therefore usually asymptomatic until hepatic metastases
have occurred when hormones can be secreted into the systemic circulation and produce
the carcinoid syndrome. It is at this time that most cases are diagnosed.
Treatment firstly requires anatomical and functional characterisation.9 Small primary
tumours can be locally resected whereas larger ones may require formal "enbloc" resection
or palliative debulking. Such operations can be very successful e.g. resection ofbronchial
primary carcinoids results in a 70% five year survival.
Since hepatic metastases produce the main symptoms but are not invariably fatal, they are
treated aggressively with the following procedures:
1. Pharmacological hormonal manipulation. Somatostatindecreasesboth thesynthesis
and release of hormones by the tumour, as well as increasing the synthesis of inhibitory
proteins. It may also prove to be anti-neoplastic and to slow tumour progression.
2. Chemotherapy with streptozotocin.
3. Surgical debulking - this isofparticular use with unilobarhepatic metastases where
a hepatic lobectomy can be performed.
4. Hepatic artery occlusion.5 7 11'2 This can beachievedby ligation orembolisation.
Formal ligation requires a laparotomy and is associated with an operative mortality and
rapid collateral formation. It produces symptomatic relief lasting a mean of five months.
Temporary occlusion can be carried out by vessel layer formation or by implanting a
tourniquet. These options reduce perioperative mortality by separating tumour necrosis
from the laparotomy. They can also be repeated, and reduce collateral formation as the
hepatic artery occlusion is only temporary.
Hepatic artery embolisation is a palliative procedure used to control pain, haemorrhage,
hormone secretion and tumour size. Any accessible tumour can be embolised but it is most
effective when used formetastatic neuroendocrine tumours. The procedure is covered with
antibioticsandsomatostatin toreducetheriskofinfectionandacarcinoidcrisisrespectively.'"
Percutaneous selective angiography is used to identify the feeding vessels of the tumour.
A shower of small particles embolises the smaller peripheral vessels, thus reducing
collateral formation (analogous to surgical isolation), and is followed by embolisation of
themainfeedingvessels.7- "Achoiceofembolising materials can beusedincluding iodized
oil, Gelfoam, Oxycel, PVC (available in graded sizes) and coils (which exclude re-
embolisation as well as concurrent intra-arterial chemotherapy). Re-embolisation can be
carriedoutfortumourregrowthortooccludesubsequentcollateralarteries. Re-embolisation
was only required in under 10% of cases within 5 years in a Swedish trial.Y'
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Palliation of symptoms occurs in almost every case and has a duration of 2-18 months
(mean 7 months) and afurther3-18 months (mean 1I months) following reembolisation. 14
Hepatic artery embolisation was initially used for bilobar hepatic metastases, where
resection is impossible, and forpatients unfit for surgery. It is now more widely used as it
has a lower morbidity and negligible mortality compared to the alternatives, and requires
less than one weekofhospitalisation. Earlierandrepeatedembolisation may also improve
patient survival.9 It also enables concurrent intra-arterial chemotherapy if a degradeable
material is used. Such acombined chemoembolisation procedure improves tumouruptake
of the chemotherapeutic agent while protecting the normal liver. This allows control of
carcinoid symptoms as well as regression or stabilisation ofthe liver tumours in 80% of
patients. 16
Asallembolisedtumoursundergoselectiveasepticnecrosis,thepostembolisation syndrome
(RUQ pain, nausea, pyrexia, leucocytosis and derangement of LFTs) is ubiquitous to a
greater orlesserextent. Symptomatic treatment in theearly stages with analgesia and anti-
emetics is sufficient.'7 Prolonged symptoms lasting more than five days should be
investigated to exclude rare complications. This would include abscesses which can be
drained percutaneously ordrained at laparotomy.5 12 Othercomplications ofembolisation
include septicaemia, carcinoid crisis, haemorrhage, gall-bladder ischaemia, pancreatic
pseudocyst, hepatic artery aneurysm formation, and embolisation ofunrelated arteries by
release of the material into the general circulation.39- '1
Embolisation is becoming increasingly popular since it produces effective clinical and
biochemical suppression ofcarcinoid metastases; itisbothsafeandinexpensive. However,
itremains apurely palliative procedure. The only real hopeforcure lies withorthoptic liver
transplantation (OLT). In a series of 1000 OLTs over6years in Pittsburgh, two cases were
forcarcinoid metastases.19 Both patients died from causes unrelated to tumour recurrence
and had no evidence ofthis at postmortem. This hopeful pointer to curative management
should be examined prospectively in a trial ofOLT against standard treatment. Early and
repeated embolisation appears to be the current safest mode of management for patients
with hepatic carcinoid metastases.
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